NO983452L - FremgangsmÕter for Õ hemme muskuloaponeurotisk fibromatose (desmoide tumorer) - Google Patents

FremgangsmÕter for Õ hemme muskuloaponeurotisk fibromatose (desmoide tumorer)

Info

Publication number
NO983452L
NO983452L NO983452A NO983452A NO983452L NO 983452 L NO983452 L NO 983452L NO 983452 A NO983452 A NO 983452A NO 983452 A NO983452 A NO 983452A NO 983452 L NO983452 L NO 983452L
Authority
NO
Norway
Prior art keywords
procedures
inhibiting
desmoid tumors
fibromatosis
inhibiting musculoaponeurotic
Prior art date
Application number
NO983452A
Other languages
English (en)
Other versions
NO983452D0 (no
Inventor
Maria L Brandi
Francesco Tonelli
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9603148.9A external-priority patent/GB9603148D0/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO983452L publication Critical patent/NO983452L/no
Publication of NO983452D0 publication Critical patent/NO983452D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Fremgangsmåte for å hemme muskuloaponeurotiske fibromateoser omfatter administre- ring til et pattetdyr som har behov for dette av en effektiv mengde av en forbindelse med formel (I), hvor R1 og R3 uavhengig av hverandre er hydrogen, -CH3, (a) eller (b), der Ar eventuelt er substituert fenyl; R2 blir valgt fra gruppen bestående av pyrrolidin, heksame- tylenimin, og piperidin; eller et farmasøytisk akseptabelt salt eller solvat derav.
NO983452A 1996-01-29 1998-07-27 FremgangsmÕter for Õ hemme muskuloaponeurotisk fibromatose (desmoide tumorer) NO983452D0 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1077396P 1996-01-29 1996-01-29
GBGB9603148.9A GB9603148D0 (en) 1996-02-15 1996-02-15 Methods of inhibiting musculoaponeurotic fibromatoses (desmoid tumors)
PCT/US1997/002287 WO1997026878A1 (en) 1996-01-29 1997-01-27 Methods of inhibiting musculoaponeurotic fibromatoses (desmoid tumors)

Publications (2)

Publication Number Publication Date
NO983452L true NO983452L (no) 1998-07-27
NO983452D0 NO983452D0 (no) 1998-07-27

Family

ID=26308707

Family Applications (1)

Application Number Title Priority Date Filing Date
NO983452A NO983452D0 (no) 1996-01-29 1998-07-27 FremgangsmÕter for Õ hemme muskuloaponeurotisk fibromatose (desmoide tumorer)

Country Status (11)

Country Link
EP (1) EP0907361A4 (no)
JP (1) JP2000503995A (no)
KR (1) KR19990082055A (no)
CN (1) CN1209746A (no)
AU (1) AU707675B2 (no)
CZ (1) CZ235398A3 (no)
EA (1) EA199800678A1 (no)
IL (1) IL125523A0 (no)
NO (1) NO983452D0 (no)
PL (1) PL328127A1 (no)
WO (1) WO1997026878A1 (no)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2135195C1 (ru) * 1998-12-17 1999-08-27 Овсюк Валерий Григорьевич Способ получения материала, содержащего клетки предстательной железы, материал, содержащий клетки предстательной железы, и способы лечения фиброматоза матки, хронического простатита и нарушений мужской половой функции методом трансплантации
AU781168B2 (en) * 2001-01-26 2005-05-12 Pfizer Products Inc. Method of treating certain cancers using an estrogen agonist/antagonist

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5552162A (en) * 1993-02-09 1996-09-03 Arch Development Corporation Method for improvement of scar size and appearance
CZ253694A3 (en) * 1993-10-15 1995-05-17 Lilly Co Eli Pharmaceutical preparation for treating resistant neoplasms
US5457116A (en) * 1993-10-15 1995-10-10 Eli Lilly And Company Methods of inhibiting uterine fibrosis
US5574047A (en) * 1993-12-21 1996-11-12 Eli Lilly And Company Methods of inhibiting imperfect tissue repair

Also Published As

Publication number Publication date
PL328127A1 (en) 1999-01-18
CZ235398A3 (cs) 1999-02-17
EP0907361A1 (en) 1999-04-14
WO1997026878A1 (en) 1997-07-31
KR19990082055A (ko) 1999-11-15
NO983452D0 (no) 1998-07-27
EA199800678A1 (ru) 1999-02-25
CN1209746A (zh) 1999-03-03
EP0907361A4 (en) 2002-05-02
AU707675B2 (en) 1999-07-15
IL125523A0 (en) 1999-03-12
AU2124097A (en) 1997-08-20
JP2000503995A (ja) 2000-04-04

Similar Documents

Publication Publication Date Title
NO973635L (no) Fremgangsmåte for hemming av celle-celle adhesjon
NO971520L (no) Fremgangsmåte for hemming av tilstander forbundet med neuropeptid Y
NO944911L (no) Ikke-peptid-takykininreseptorantagonister
RU94045846A (ru) Применение производных бензотиофена для ингибирования тромбина
NO990671L (no) Muskarinantagonistiske etere
DK0652005T3 (da) Fremgangsmåder til inhibering af endometriose
NO944927L (no) Fremgangsmåte for inhibering av pulmonar hypertensiv sykdom
DK0651999T3 (da) Fremgangsmåder til inhibering af livmoderfibrose
DK0659417T3 (da) Fremgangsmåder til inhibering af dysfunktionel blødning fra livmoderen
NO944914L (no) Fremgangsmåte for å inhibere autoimmunsykdommer
MX9701325A (es) Metodos para inhibir la mucositis ulcerativa.
MX9701360A (es) Metodos para la inhibicion de la desmielinizacion y las enfermedades de la dismielinizacion.
NO944926L (no) Fremgangsmåter for å inhibere myeloperoksidaseaktivitet
UA32427C2 (uk) Застосування бензотіофенів або їх фармацевтично прийнятних солей або сольватів для інгібування ангіогенезу і/або ангіогенних захворювань
NO944924L (no) Fremgangsmåter for inhibering av Turner's syndrom
NO944933L (no) Fremgangsmåte for å inhibere sykdomstilstander i brystet
NO975580L (no) Fremgangsmåte for å inhibere melanom
NO970786L (no) Fremgangsmåte for hemming av benprotesedegradering
NO944931L (no) Anvendelse av 2-fenyl-3-aroylbenzotiofener for inhibering av tidlig seksuell modenhet
NO981578L (no) FremgangsmÕte for hemming av plasminogenaktivatorhemmer I
NO973367L (no) Fremgangsmåte for å inhibere miljömessige östrogen
NO983452L (no) FremgangsmÕter for Õ hemme muskuloaponeurotisk fibromatose (desmoide tumorer)
NO973609L (no) Fremgangsmåte for å inhibere effektene av IL-6
NO20000750L (no) FremgangsmÕte for Õ redusere blodplatetall
NO970783L (no) Fremgangsmåte for å hindre endometrialkreft

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application